ADVI Health

Last month, ADVI Health's head of policy, research, and analysis, Lindsay Bealor Greenleaf, participated in Managed Healthcare Executive's webinar, "What 'Going Wild' on Healthcare Could Mean: The Early Days of Trump Healthcare," where she shared insights on different factors of the new administration, such as RFK Jr.'s confirmation, the future of the #InflationReductionAct (IRA) drug price negotiations and PBM reform, #Medicare Advantage, and more. Tune into the full webinar: https://lnkd.in/gK5TDm9d

#ICYMI: ADVI Health's vice president, strategic analytics, value and economics (SAVEs), Peter Kardel, was included in a Specialty Pharmacy Continuum article, sharing insight on the rate of CRS occurrence in CAR-T therapy clinical trials. Pete discusses ADVI's assessment of CAR-T cases covered in #Medicare, revealing that the rate of CRS was significantly lower for beneficiaries receiving CAR-T as outpatients compared to the inpatient setting. Read more insights: https://lnkd.in/eMvjRu4F

?? #HiringAlert: ADVI Health's business development team is seeking a sales operations senior associate to join the team, who will solve issues through data-informed commercialization, #marketaccess, and policy expertise. This role will execute our lead generation approach, optimizing our sales processes, customer relationship management (CRM) system, HubSpot, and other lead generation tech tools. The role will generate leads, develop insightful reports and dashboards, ensure data integrity, and provide analytical support to our #sales team. Learn more and apply today: https://lnkd.in/eATsQFi2

?? Join us in welcoming John Coster to ADVI Health as senior director, federal agency engagement, and co-lead of ADVI's #InflationReducationAct (IRA) Center of Excellence. Before joining ADVI, John spent 10 years at the Centers for Medicare & Medicaid Services (CMS), serving as professional staff in both the #Medicare Part D and #Medicaid drug programs. He lobbied on Capitol Hill for independent and chain pharmacies and worked for Senator David Pryor on #drugpricing issues earlier in his career. Learn more about John: https://lnkd.in/gdd2jM8K

Last month, ADVI Health's vice president, #marketaccess, Yana Volman, attended BioLife Summits' Annual Texas BioLife Summit in Dallas, TX and participated in panel discussions "Tackling the Market Approval Process" and “Devices and Diagnostics: Where Health and Innovation Meet”, sharing insights on the different paths of getting a new drug, product, or technology to market with the least amount of resistance. Reflecting on the event, Yana shares her key takeaways, including maximizing a product's availability by applying a market access lens early in the beginning stages of clinical programs. Learn more about ADVI's market access expertise and get in touch with our #ADVIExperts:?https://lnkd.in/eCh3_sQx

Are you attending AMCP's 2025 annual meeting on March 31-April 3 in Houston, TX? Meet with #ADVIExperts Caitlin Sheetz and Will Burchenal and learn more about how ADVI Health can support your team with data-informed commercialization, market access, and policy expertise. Get in touch with your ADVI #AMCP2025 team: https://lnkd.in/gbgzswas

Each year the Health Resources and Services Administration (HRSA) conducts audits of 340B covered entities to manage compliance risks. ADVI Health analyzed historic audit data and found that the majority of finalized 340B audits between FY2017 and FY2023 had at least one adverse finding, indicating consistent non-compliance in the samples. Additionally, despite the exponential growth in the number of covered entity sites (more than 60,000 in 2024), HRSA limits audits to just 200 sites per year (less than half a percent). ? ADVI's federal and state policy solution team breaks down more insights and findings in a recent #ADVIAnalysis: https://lnkd.in/g5dgsjYC

Recent policy changes are undermining the bipartisan support for rare disease patients and creating additional barriers to orphan drug development. #LifeSciences manufacturers need guidance on how to stay on top of the latest state policy trends. Learn how our ADVI Health federal and state policy solution team worked with manufacturers to identify state laws, as well as proposed legislation, that could provide the opportunity to engage state policymakers on the importance of orphan drug development and the challenges of rare disease patients. Read the full case study: https://lnkd.in/efRag-ct

Errors in the workplace are common, as humans are prone to make mistakes, but can be more detrimental in the medical field. In the recent releases of his "Decoding Health Care" series, ADVI Health senior advisor, Michael Kolodziej, MD, discusses medical errors and medical malpractice, sharing insights on the practices that have been implemented in the industry over the years to minimize the risk of errors, in addition to the main reasons for medical malpractice lawsuits. Read more: https://lnkd.in/gagFKWB9

In recent years, states have increasingly enacted prescription drug affordability boards (PDABs), with some expressing concerns over possible implications of accessibility to care, including products treating rare diseases and conditions. ? For the recent observance of #RareDiseaseDay, ADVI Health's federal and state policy team analyzed the four main processes of PDABs and reviewed the 2025 state of play. Several PDABs are expected to set and potentially begin implementation of upper payment limits (UPLs) this year, and 12 states have already proposed new PDAB legislation. ? Read the full case study from our #ADVIExperts: https://lnkd.in/eB_JcfYs